EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hemodynamic Effects of Interfacility Dexmedetomidine Infusions During Transport of Patients with Alpha-2-adrenergic Agonist Withdrawal

Scott Goldstein, Nathaniel Zahustecher, Derek Isenberg, Eric Rosen, Celine Bennett

Western Journal of Emergency Medicine · 2026

DOI: 10.5811/westjem.62953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Western Journal of Emergency Medicine, 2026. Verfasst von Scott Goldstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Temple Transport Team, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Dexmedetomidine, Adrenergic alpha-2 Receptor Agonists, Hemodynamics, Substance Withdrawal Syndrome. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the Philadelphia region, there has been an increase in the potency of illicit opioids as well as the addition of nonopioid adulterants. Currently, medetomidine, a veterinary anesthetic that acts as an alpha-2-adrenergic agonist, is a common adulterant in the illicit opioid supply, causing both unique overdose and withdrawal syndromes. Although opioid withdrawal alone is not deadly, with added adulterants, especially medetomidine, this is no longer the case. Dexmedetomidine is an alpha-2-adrenergic agonist frequently used for sedation in the emergency department and intensive care unit. Dexmedetomidine is also used off-label to treat the life-threatening withdrawal from alpha-2-agonists.

Objective

This study describes the dosing and hemodynamic effects associated with the interfacility administration of dexmedetomidine in patients with alpha-2 adrenergic agonist withdrawal. Secondarily, we describe the safety of dexmedetomidine in this patient population.

Methods

We conducted a retrospective case review of patients receiving dexmedetomidine infusions in the interfacility setting for presumed alpha-2–adrenergic agonist withdrawal. Demographic data, dosing, and vital signs were analyzed descriptively.

Results

Over a six-month period, of 217 cases identified, 182 contained complete hemodynamic data. The average age was 39.5 years, and 67% were male. The average transport time was 15.7 minutes (range, 5-40 minutes). The mean dexmedetomidine infusion rate was 1.32 (0.31) mcg/kg/hr. The average mean arterial pressure decreased from 122.1 mm Hg (21.7) at the time of initial patient contact to 118.3 mm Hg (21.7) (mean difference, 3.80; 95% CI, 1.96-5.64) at final patient interaction. Heart rate also showed a minimal change from 104.9 (23.7) to 103.6 (21.8) beats/min (mean 1.3; 95% CI, -0.48 to 3.08). No cases of severe hypotension or clinically significant bradycardia requiring intervention were documented (one-sided 95% CI, 0-1.7%).

Conclusion

In this case series of patients, prehospital dexmedetomidine infusions to treat alpha-2-agonist withdrawal were associated with stable hemodynamics without significant bradycardia or hypotension. These findings support the safety of dexmedetomidine infusions for interfacility transport and provide a rationale for examining whether advanced life support clinicians can safely transport patients receiving dexmedetomidine infusions for this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineAdrenergic alpha-2 Receptor AgonistsHemodynamicsSubstance Withdrawal SyndromeHypnotics and SedativesPatient TransferHumansRetrospective StudiesFemaleMaleAdultInfusions, IntravenousMiddle Aged

Substanzen

DexmedetomidineAdrenergic alpha-2 Receptor AgonistsHypnotics and Sedatives

Autor:innen und Institutionen

  • Temple Transport Team, Philadelphia, Pennsylvania.
  • Temple University Hospital, Department of Emergency Medicine, Division of Emergency Medical Services, Philadelphia, Pennsylvania.
  • Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.

Zitieren

APA

Goldstein, S., Zahustecher, N., Isenberg, D., Rosen, E., & Bennett, C. (2026). Hemodynamic Effects of Interfacility Dexmedetomidine Infusions During Transport of Patients with Alpha-2-adrenergic Agonist Withdrawal. Western Journal of Emergency Medicine. https://doi.org/10.5811/westjem.62953

Vancouver

Goldstein S, Zahustecher N, Isenberg D, Rosen E, Bennett C. Hemodynamic Effects of Interfacility Dexmedetomidine Infusions During Transport of Patients with Alpha-2-adrenergic Agonist Withdrawal. Western Journal of Emergency Medicine. 2026. doi:10.5811/westjem.62953

BibTeX
@article{Goldstein2026,
  author = {Goldstein, Scott and Zahustecher, Nathaniel and Isenberg, Derek and Rosen, Eric and Bennett, Celine},
  title = {Hemodynamic Effects of Interfacility Dexmedetomidine Infusions During Transport of Patients with Alpha-2-adrenergic Agonist Withdrawal},
  journal = {Western Journal of Emergency Medicine},
  year = {2026},
  doi = {10.5811/westjem.62953}
}
Kostenlos starten →